 |
|
|
|
 |
|
|
| Article 1 to 10 out of 14 concerning Wyeth Pharmaceuticals
|
-
Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
(03 Mar 2008)
Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA
Dyax Corp. announced that Wyeth Pharmaceuticals, a division of Wyeth, recently received market approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free), a recombinant factor VIII ...
-
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals announce receipt of an FDA action letter for bifeprunox
(14 Aug 2007)
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced the receipt of an action letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for bifeprunox, an atypical ...
-
Crucell Announces PER.C6 and AdVac Technology License Agreement with Wyeth Pharmaceuticals
(31 Jul 2007)
Crucell N.V. announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth. Under the terms of the agreement, Crucell will receive an upfront payment, milestone ...
-
Wyeth wins world award for investment in Scotland
(03 Jul 2007)
Translational Medicine Research Collaboration Scoops "Best Investment in Europe" Award at La Baule
Wyeth Pharmaceuticals, a division of Wyeth, was awarded one of three "Best Investment in Europe" titles at the La Baule World Investment Conference for its leading role in creating the world's first Translational Medicine Research Collaboration ...
-
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
(04 Jun 2007)
Wyeth Pharmaceuticals, a division of Wyeth, announced that the U.S. Food and Drug Administration (FDA) has approved TORISEL(TM) (temsirolimus) for patients with advanced renal cell carcinoma (RCC). According to the company, TORISEL is the first ...
-
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
(06 Feb 2007)
Wyeth Pharmaceuticals, a division of Wyeth, and Nautilus Biotech in Evry, France, announced the signing of a research collaboration and license agreement to discover and develop novel recombinant Factor IX proteins for the treatment of hemophilia B. ...
-
elbion and Wyeth Enter Collaboration to Develop New Treatments for Schizophrenia
(06 Feb 2007)
elbion NV announced it has entered a research and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, around elbion's phosphodiesterase 10 (PDE10) program for CNS disorders with an initial focus on schizophrenia.The agreement includes ...
-
Translational Medicine Research Collaboration announces first round research project funding
(10 Jan 2007)
The Translational Medicine Research Collaboration (TMRC) announced the first round of research projects to be funded through the new £50 million initiative. Almost £8 million of funding has been released to support 28 new research projects covering ...
-
Ablynx enters into research and license agreement with Wyeth
(07 Nov 2006)
Ablynx, has announced that they have entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover, develop and commercialise Nanobodies® directed at the tumour necrosis factor ...
-
Wyeth and Progenics Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Methylnaltrexone
(29 Dec 2005)
Wyeth Pharmaceuticals, a division of Wyeth and Progenics Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone (MNTX) for the treatment of ...
Additional information
Wyeth Pharmaceuticals
Collegeville, PA, United States of America
Company
|
|
|
|
|
|
Top
